TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Company Overview - TG Therapeutics, Inc. has completed a $100 million share repurchase program, initially announced in August 2024, repurchasing approximately 3.5 million shares at an average price of $28.55 per share [1][3] - The Board of Directors has authorized a new share repurchase program for an additional $100 million of common stock, which may be executed through various means depending on market conditions [2] Financial Performance - In August 2025, the company repurchased about $78 million worth of stock, indicating a strategic move to enhance shareholder value [3] - The company believes that current market prices do not reflect the potential of its product BRIUMVI and its long-term growth prospects [3] Product Information - BRIUMVI (ublituximab-xiiy) is a novel monoclonal antibody targeting CD20-expressing B-cells, designed for efficient B-cell depletion at low doses [4] - It is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) in the U.S. and Europe, including various specific conditions [5][24] Market Position - TG Therapeutics is focused on the acquisition, development, and commercialization of treatments for B-cell diseases, with BRIUMVI being a key product approved by regulatory agencies in multiple regions [24]